Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX™ Therapy For Hemophilia B
Idec (NASDAQ: BIIB) announced that Health Canada has approved
™ [Coagulation Factor IX (Recombinant), Fc Fusion
Protein], for the control and prevention of bleeding episodes and
Today Biogen Idec (NASDAQ: BIIB) announced that Health Canada has approved ALPROLIX ™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and is indicated to prevent or reduce the frequency of bleeding episodes with prophylactic (protective) infusions starting at once weekly or once every 10-14 days. This is the first regulatory approval worldwide for ALPROLIX, which is currently under review by regulatory authorities in several other countries, including the United States, Australia and Japan. “Health Canada’s approval of ALPROLIX marks the first significant treatment advance in hemophilia B in 17 years, and reinforces our commitment to developing innovative therapies that help address the critical needs of the hemophilia community,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “We believe that the safety, efficacy and prophylactic dosing schedule demonstrated with ALPROLIX will provide people with hemophilia B a meaningful new way to manage their condition.” The World Federation of Hemophilia recommends a prophylactic (prevention of bleeding) regimen as the goal of treatment for people with severe hemophilia. 1,2,3 Guidelines established by the Medical and Scientific Advisory Council of the National Hemophilia Foundation recommend prophylactic infusions two or more times a week with traditional hemophilia treatments. 4 Frequent prophylactic infusions can be a burden to people with hemophilia and may reduce adoption to this type of treatment regimen. 5 The Health Canada approval of ALPROLIX is based on results from the global, Phase 3 B-LONG study, the largest registrational study in hemophilia B ever completed. It demonstrated that ALPROLIX safely and effectively prevented, or reduced, bleeding episodes with prophylactic infusions given once weekly or once every 10-14 days in adults and adolescents with severe hemophilia B. In addition, more than 90 percent of all bleeding episodes were controlled by a single ALPROLIX infusion.
At a time when healthcare investors seem especially primed for big, transformative biotech M&A, a deal in which Celgene acquires Biogen would be smart, profitable, opportunistic and certainly attention grabbing.